Inventor · disambiguated record
Marilyn Kehry
Also filed as: KEHRY MARILYN · KEHRY MARILYN R
15 granted patents·18 pending applications·118 citations·filing 1995–2025
93Inventor score
Files withANAPTYSBIO INC16MOMENTA PHARMACEUTICALS INC5BOEHRINGER INGELHEIM PHARMA3CELGENE CORP3TESARO INC3
Top patents by PatentIndex Score
33 records- 0196US10738117B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2017·Granted Aug 11, 2020·10 cites·9 claims
- 0295US9815897B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2014·Granted Nov 14, 2017·24 cites·44 claims
- 0394US10676526B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2016·Granted Jun 9, 2020·9 cites·19 claims
- 0491US10508149B2Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2016·Granted Dec 17, 2019·7 cites·25 claims
- 0590US11753472B2Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2021·Granted Sep 12, 2023·2 cites·19 claims
- 0688US10428145B2PD-1 binding proteins and methods of use thereofCELGENE CORP·Filed 2016·Granted Oct 1, 2019·10 cites·155 claims
- 0787US11345751B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2017·Granted May 31, 2022·4 cites·40 claims
- 0887US11155624B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2017·Granted Oct 26, 2021·4 cites·14 claims
- 0985US11352427B2Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2019·Granted Jun 7, 2022·2 cites·10 claims
- 1083US11732047B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2020·Granted Aug 22, 2023·1 cites·26 claims
- 1182US2023331843A1Antibodies Directed Against Programmed Death-1(PD-1)ANAPTYSBIO INC·Filed 2023·Application pending·0 cites
- 1278US2024158508A1FcRn Antibodies and Methods of Use ThereofMOMENTA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1376US2023416368A1Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2023·Application pending·0 cites
- 1474US10150817B2Rapid generation of anti-idiotypic antibodiesDUNN ROBERT J·Filed 2011·Granted Dec 11, 2018·3 cites·25 claims
- 1573US10836824B2Antibodies directed against lymphocyte activation gene 3 (LAG-3)ANAPTYSBIO INC·Filed 2016·Granted Nov 17, 2020·1 cites·10 claims
- 1673US5817516AMethods for proliferating and differentiating B cells with high density membrane CD40 ligandBOEHRINGER INGELHEIM PHARMA·Filed 1995·Granted Oct 6, 1998·31 cites·14 claims
- 1773US2025368739A1Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2025·Application pending·0 cites
- 1870US2023272076A1PD-1 Binding Proteins and Methods of Use ThereofCELGENE CORP·Filed 2022·Application pending·0 cites
- 1969US2021163589A1Antibodies Directed Against Programmed Death-1(PD-1)ANAPTYSBIO INC·Filed 2020·Application pending·0 cites
- 2069US2022363759A1Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)ANAPLYSBIO INC·Filed 2022·Application pending·0 cites
- 2165US2024158495A1Antibody Agents Directed Against Lymphocyte Activation Gene-3 (LAG-3) and Uses ThereofTESARO INC·Filed 2023·Application pending·0 cites
- 2264US2023049725A1FcRn Antibodies and Methods of Use ThereofMOMENTA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2364US2021095026A1Antibodies Directed Against Lymphocyte Activation Gene 3 (LAG-3)ANAPTYSBIO INC·Filed 2020·Application pending·0 cites
- 2462US2019256596A1Antibodies directed against lymphocyte activation gene 3 (lag-3)ANAPTYSBIO INC·Filed 2019·Application pending·0 cites
- 2561US2020255525A1Pd-1 binding proteins and methods of use thereofCELGENE CORP·Filed 2019·Application pending·0 cites
- 2661US2022089739A1Antibodies Directed Against Programmed Death-1 (PD-1)TESARO INC·Filed 2021·Application pending·0 cites
- 2757US2019284280A1Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)ANAPTYSBIO INC·Filed 2017·Application pending·0 cites
- 2853US2022135670A1Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereofTESARO INC·Filed 2018·Application pending·0 cites
- 2950US6297052B1B cell culture system comprising high density membrane bound CD40 ligandBOEHRINGER INGELHEIM PHARMA·Filed 1997·Granted Oct 2, 2001·7 cites·14 claims
- 3046US2007136826A1Anti-mouse CD20 antibodies and uses thereofBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 3145US2023391872A1B and t lymphocyte attenuator (btla) modulators and method of using sameANAPTYSBIO INC·Filed 2021·Application pending·0 cites
- 3241US2022235132A1Pd-1 agonist and method of using sameANAPTYSBIO INC·Filed 2020·Application pending·0 cites
- 3331US6143507AHigh throughput compatible assay for receptor-TRAF interactionsBOEHRINGER INGELHEIM PHARMA·Filed 1998·Granted Nov 7, 2000·3 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Marilyn Kehry files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →